Logo

RKDA

Arcadia Biosciences, Inc.

RKDA

Arcadia Biosciences, Inc. • NASDAQ
$3.75 ▲ 4.17% (+0.15)
Market Cap $5.12 M
52w High $10.31
52w Low $2.53
Dividend Yield 0%
P/E -1.02
Volume 291
Outstanding Shares 1.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.302M ▼ $1.57M ▲ $856K ▲ 65.745% ▲ $0.62 ▲ $858K ▲
Q2-2025 $1.455M ▲ $1.132M ▲ $-4.458M ▼ -306.392% ▼ $-3.26 ▼ $-1.486M ▼
Q1-2025 $1.2M ▼ $-12K ▼ $2.599M ▲ 216.583% ▲ $1.9 ▲ $-1.207M ▲
Q4-2024 $1.216M ▼ $2.668M ▲ $-4.064M ▼ -334.211% ▼ $-1.18 $-2.258M ▼
Q3-2024 $1.537M $2.265M $-1.612M -104.88% $-1.18 $-1.753M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.885M ▲ $8.584M ▲ $3.141M ▼ $5.443M ▲
Q2-2025 $4.443M ▲ $7.788M ▼ $3.255M ▼ $4.533M ▼
Q1-2025 $3.159M ▼ $12.99M ▼ $4.085M ▼ $8.905M ▲
Q4-2024 $4.242M ▼ $13.517M ▼ $7.294M ▲ $6.223M ▼
Q3-2024 $6.576M $15.241M $5.092M $10.287M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $856K ▲ $-257K ▲ $0 ▼ $1K ▲ $-256K ▲ $-257K ▲
Q2-2025 $-4.458M ▼ $-2.033M ▼ $250K ▼ $0 ▼ $-1.783M ▼ $-2.033M ▼
Q1-2025 $2.599M ▲ $-1.588M ▲ $500K ▼ $5K ▲ $-1.083M ▼ $-1.588M ▲
Q4-2024 $-4.064M ▼ $-2.209M ▼ $2.515M ▲ $0 ▼ $306K ▲ $-2.209M ▼
Q3-2024 $-1.182M $-1.752M $180K $4K $-1.568M $-1.752M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Arcadia’s income statement shows a very small, almost flat revenue base and recurring losses year after year. The core issue is scale: the company hasn’t built enough sales volume to cover its ongoing operating costs. While losses have narrowed slightly from earlier years, the business is still far from break-even and depends on external funding and asset sales rather than profits. The extremely negative per‑share figures mainly reflect multiple reverse stock splits, not just business performance, but they underline how long losses have persisted.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base and limited cash compared with what most operating companies would need to grow. On the positive side, Arcadia currently carries little to no financial debt, so it is not heavily burdened by interest payments. However, equity has been gradually eroded by repeated losses, leaving only a modest capital cushion. This profile suggests limited financial flexibility and a need to be careful with cash management until a more sustainable business model is established, especially through the pending merger.

Cash Flow

Cash Flow Cash flow has consistently been negative from operations, meaning the company spends more cash running the business than it brings in from customers. Free cash flow is also negative, although capital spending has been very low, so the cash burn is mainly operating expenses rather than big investment projects. This pattern indicates a dependence on raising capital or selling assets to keep funding the business. Any improvement will likely come from cost discipline, successful brand monetization, or new cash inflows tied to strategic transactions.

Competitive Edge

Competitive Edge Arcadia’s historical edge came from its proprietary GoodWheat traits and related intellectual property, which gave it a clear niche in specialty wheat. That moat has effectively been sold off with the transfer of GoodWheat and key patents to Corteva. The company’s remaining consumer focus, the Zola coconut water brand, plays in a very crowded beverage category with strong, well‑funded competitors and limited built‑in protection from imitation. Looking ahead, the planned merger with Roosevelt Resources shifts Arcadia toward energy and carbon capture, where it will be a very small player in a technically complex, capital‑intensive field, likely requiring strong partners to achieve scale.

Innovation and R&D

Innovation and R&D Arcadia historically invested in plant breeding and genomics, building a solid patent portfolio around non‑GMO wheat traits. Those innovations were real and differentiated, but many of the most valuable assets have now been monetized and sold. With the move away from agricultural biotech toward Zola and a future in oil, gas, and carbon capture, the company’s innovation story becomes less about in‑house ag science and more about how effectively it can develop or partner for new technologies in the energy space. That transition introduces uncertainty: the company is stepping into areas with different technical demands, regulatory frameworks, and R&D needs, and it is not yet clear what its long‑term innovation engine will look like post‑merger.

Summary

Arcadia Biosciences is in the middle of a fundamental transformation. Financially, it remains a very small, loss‑making company with a thin asset base, modest cash, no meaningful debt, and a history of reverse splits—signals of prolonged difficulty scaling a profitable business. Strategically, it has exited most of what originally defined it (GoodWheat and agricultural biotech) and is leaning on Zola coconut water while preparing to effectively reinvent itself again through a merger into an oil, gas, and carbon capture venture. The result is a story with high uncertainty: past financials reflect a struggling ag‑bio platform, while the future depends on successful execution in completely different industries with their own risks, timeframes, and capital requirements.

NEWS

November 7, 2025 · 4:05 PM UTC

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

Read more